Skip to main content
SpringerLink
Log in

Treatment of Inflammatory Choroidal Neovascular Membranes

  • Chapter
  • First Online:
Complications in Uveitis

  • 502 Accesses

Abstract

Choroidal neovascularization (CNV) represents a severe sight-threatening occurrence in patient with inflammation of the uveal tract. CNV might can be secondary to both infectious and noninfectious uveitis.

After an appropriate assessment of the uveal inflammation by fluorescein angiography (FA), indocyanine green angiography (ICGA) and optical coherence tomography (OCT) and OCT angiography, a prompt and effective therapeutic strategy has to be planned.

Infectious uveitis complicated by CNV has to treated by targeting the infectious disease itself primarily and by associating therapies directly targeting the neovascular process, such as the intravitreal anti-Vascular Endothelial Growth Factor (VEGF) agents. In specific cases, an adjuvant therapy by steroids might appropriate.

The treatment strategy for CNV secondary to noninfectious uveitis should aim primarily the control of the inflammation control. The association of steroids with immunosuppressive agents is most appropriate therapy for inflammatory CNV. Anti-VEGF agents are commonly associated with systemic therapy.

Although there is no comparative study between immunosuppressive agents, mycophenolate mofetil seems to offer a promising profile for the long term control of non-infectious inflammatory CNV.

Although a series of publications reported different treatment strategies for inflammatory neovascularization, there is no guideline available till now.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Arnold JJ, Campain A, Barthelmes D, et al. Two-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology. 2015;122(6):1212–9.

    PubMed  Google Scholar 

  2. Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina. 2010;30(9):1333–49.

    PubMed  Google Scholar 

  3. Wu K, Zhang X, Su Y, et al. Clinical characteristics of inflammatory choroidal neovascularization in a Chinese population. Ocul Immunol Inflamm. 2016;24(3):261–7.

    CAS  PubMed  Google Scholar 

  4. Shoughy SS, Jaroudi MO, Tabbara KF. Regression of peripapillary choroidal neovascular membrane in a patient with sarcoidosis after oral steroid therapy. Saudi J Ophthalmol. 2014;28(2):160–2.

    PubMed  PubMed Central  Google Scholar 

  5. Nobrega MJ, et al. Anecortave may help choroidal neovascularization regression in serpiginous choroiditis. Can J Ophthalmol. 2007;42(1):151–2.

    PubMed  Google Scholar 

  6. Mansour AM, Arevalo JF, Fardeau C, et al. Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization. Can J Ophthalmol. 2012;47(3):269–74.

    PubMed  Google Scholar 

  7. Gillies MC, Campain A, Walton R, et al. Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab. Ophthalmology. 2015;122(3):589–94.e1.

    PubMed  Google Scholar 

  8. Adán A, Mateo C, Navarro R, Bitrian E, Casaroli-Marano RP. Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina. 2007;27(9):1180–6.

    PubMed  Google Scholar 

  9. Hohberger B, Rudolph M, Bergua A. Choroidal neovascularization associated with punctate inner choroidopathy: combination of intravitreal anti-VEGF and systemic immunosuppressive therapy. Case Rep Ophthalmol. 2015;6(3):385–9.

    PubMed  PubMed Central  Google Scholar 

  10. Ganesh S, Ahmed A, Biswas J. Analysis of the clinical profile and management of inflammatory choroidal neovascular membranes in uveitic eyes: a study from a tertiary referral center. Ocul Immunol Inflamm. 2019;27:424–34.

    PubMed  Google Scholar 

  11. Arrevola L, Acero MA, Peral MJ. Two-year outcome of aflibercept for the treatment of choroidal neovascularization in punctate inner choroidopathy. Case Rep Ophthalmol. 2019;10(1):24–31.

    PubMed  PubMed Central  Google Scholar 

  12. Kramer M. Photodynamic therapy for inflammatory CNV: do we know enough? Ocul Immunol Inflamm. 2005;13(5):331–3.

    PubMed  Google Scholar 

  13. Mansour AM, Mackensen F, Arevalo JF, Ziemssen F, Mahendradas P, Mehio-Sibai A, Hrisomalos N, Lai TY, Dodwell D, Chan WM, Ness T, Banker AS, Pai SA, Berrocal MH, Tohme R, Heiligenhaus A, Bashshur ZF, Khairallah M, Salem KM, Hrisomalos FN, Wood MH, Heriot W, Adan A, Kumar A, Lim L, Hall A, Becker M. Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol. 2008;146(3):410–6.

    CAS  PubMed  Google Scholar 

  14. Tavallali A, Yannuzzi LA. Idiopathic multifocal choroiditis. J Ophthalmic Vis Res. 2016;11(4):429–32.

    PubMed  PubMed Central  Google Scholar 

  15. Tsaousis KT, Nassr M, Kapoor B, Konidaris VE, Tyradellis S, Empeslidis T. Long-term results of intravitreal bevacizumab and dexamethasone for the treatment of punctate inner choroidopathy associated with choroidal neovascularization: a case series. SAGE Open Med Case Rep. 2018;6:2050313X18772478.

    PubMed  PubMed Central  Google Scholar 

  16. Chen SN, Chen YL, Yang BC. Long-term outcome of punctate inner choroidopathy or multifocal choroiditis with active choroidal neovascularization managed with intravitreal bevacizumab. Ocul Immunol Inflamm. 2019:1–6. https://doi.org/10.1080/09273948.2019.1588335.

  17. Arevalo JF, Adan A, Berrocal MH, Espinoza JV, Maia M, Wu L, Roca JA, Quiroz-Mercado H, Ruiz-Moreno JM, Serrano MA, Pan-American Collaborative Retina Study Group. Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months. Retina. 2011;31(2):353–63.

    CAS  PubMed  Google Scholar 

  18. Fine HF, Zhitomirsky I, Freund KB, Barile GR, Shirkey BL, Samson CM, Yannuzzi LA. Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis. Retina. 2009;29(1):8–12.

    PubMed  Google Scholar 

  19. Schadlu R, Blinder KJ, Shah GK, Holekamp NM, Thomas MA, Grand MG, Engelbrecht NE, Apte RS, Joseph DP, Prasad AG, Smith BT, Sheybani A. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Am J Ophthalmol. 2008;145(5):875–8.

    CAS  PubMed  Google Scholar 

  20. Wu K, Zhang X, Su Y, Ji Y, Zuo C, Li M, Wen F. Clinical characteristics of inflammatory choroidal neovascularization in a Chinese population. Ocul Immunol Inflamm. 2016;24(3):261–7.

    CAS  PubMed  Google Scholar 

  21. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148(1):43–58.e1.

    CAS  PubMed  Google Scholar 

  22. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol. 2008;145(2):239–48.e5.

    CAS  PubMed  Google Scholar 

  23. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–48.

    PubMed  Google Scholar 

  24. Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121(3):682–92.e2.

    PubMed  Google Scholar 

  25. Spiteri Cornish K, Williams GJ, Gavin MP, Imrie FR. Visual and optical coherence tomography outcomes of intravitreal bevacizumab and ranibizumab in inflammatory choroidal neovascularization secondary to punctate inner choroidopathy. Eur J Ophthalmol. 2011;21(4):440–5.

    Google Scholar 

  26. Heier JS, Brown D, Ciulla T, Abraham P, Bankert JM, Chong S, Daniel PE Jr, Kim IK. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology. 2011;118(1):111–8.

    PubMed  Google Scholar 

  27. Roy R, Saurabh K, Bansal A, Kumar A, Majumdar AK, Paul SS. Inflammatory choroidal neovascularization in Indian eyes: etiology, clinical features, and outcomes to anti-vascular endothelial growth factor. Indian J Ophthalmol. 2017;65(4):295–300.

    PubMed  PubMed Central  Google Scholar 

  28. Invernizzi A, Pichi F, Symes R, Zagora S, Nguyen V, Erba S, Xhepa A, De Simone L, Cimino L, Gillies MC, McCluskey PJ. Twenty-four month outcomes of inflammatory choroidal neovascularization treated with intravitreal anti vascular endothelial growth factors: a comparison between two treatment regimens. Abstract 3859, ARVO Annual Meeting, Vancouver Convention Centre, Vancouver, BC, Canada.

    Google Scholar 

  29. McGarry T, Biniecka M, Veale DJ, Fearon U. Hypoxia, oxidative stress and inflammation. Free Radic Biol Med. 2018;125:15–24.

    CAS  PubMed  Google Scholar 

  30. Chen M, Rajapakse D, Fraczek M, Luo C, Forrester JV, Xu H. Retinal pigment epithelial cell multinucleation in the aging eye – a mechanism to repair damage and maintain homoeostasis. Aging Cell. 2016;15(3):436–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Balne PK, Agrawal R, Au VB, Lee B, Ghosh A, Sethu S, Agrawal M, Narayanan R, Connolly J. Dataset of plasma and aqueous humor cytokine profiles in patients with exudative age related macular degeneration and polypoidal choroidal vasculopathy. Data Brief. 2018;19:1570–3.

    PubMed  PubMed Central  Google Scholar 

  32. Flaxel CJ, Owens SL, Mulholland B, Schwartz SD, Gregor ZJ. The use of corticosteroids for choroidal neovascularisation in young patients. Eye (Lond). 1998;12(Pt 2):266–72.

    Google Scholar 

  33. Martidis A, et al. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J Ocul Pharmacol Ther. 1999;15(5):425–8.

    CAS  PubMed  Google Scholar 

  34. Dibas A, Yorio T. Glucocorticoid therapy and ocular hypertension. Eur J Pharmacol. 2016;787:57–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Dees C, et al. Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Arch Ophthalmol. 1998;116(11):1456–61.

    CAS  PubMed  Google Scholar 

  36. Nussenblatt RB, et al. The treatment of multifocal choroiditis associated choroidal neovascularization with sirolimus (rapamycin). Acta Ophthalmol Scand. 2007;85(2):230–1.

    PubMed  Google Scholar 

  37. Neri P, Manoni M, Fortuna C, Lettieri M, Mariotti C, Giovannini A. Association of systemic steroids and mycophenolate mofetil as rescue therapy for uveitic choroidal neovascularization unresponsive to the traditional immunosuppressants: interventional case series. Int Ophthalmol. 2010;30(5):583–90.

    PubMed  Google Scholar 

  38. Neri P, Mariotti C, Cimino L, Mercanti L, Giovannini A. Long-term control of cystoid macular oedema in noninfectious uveitis with Mycophenolate mofetil. Int Ophthalmol. 2009;29(3):127–33.

    PubMed  Google Scholar 

  39. Vitale AT, Foster CS. Corticosteroids. In: Vitale AT, Foster CS, editors. Diagnosis and treatment of uveitis. Philadelphia: W.B. Saunders Company; 2002. p. 142–58.

    Google Scholar 

  40. Ferrante P, Ramsey A, Bunce C, Lightman S. Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Exp Ophthalmol. 2004;32:563–8.

    PubMed  Google Scholar 

  41. Llop SM, Papaliodis GN. Cataract surgery complications in uveitis patients: a review article. Semin Ophthalmol. 2018;33(1):64–9.

    PubMed  Google Scholar 

  42. Neri P, Azuara-Blanco A, Forrester JV. Incidence of glaucoma in patients with uveitis. J Glaucoma. 2004;13(6):461–5.

    PubMed  Google Scholar 

  43. Kilmartin DJ, Forrester JV, Dick AD. Cyclosporine-induced resolution of choroidal neovascularization associated with sympathetic ophthalmia. Arch Ophthalmol. 1998;116(2):249–50.

    CAS  PubMed  Google Scholar 

  44. Neri P, Arapi I. Inflammatory choroidal neovascularization: how combined anti‐VEGF and inflammation suppressive therapy is going to become the treatment of choice. Acta Ophthalmologica, 89(s248).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Eye Institute, Cleveland Clinic Abu Dhabi/Case Western Reserve University, Abu Dhabi, UAE

    Piergiorgio Neri

Authors
  1. Piergiorgio Neri
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cleveland Clinic Abu Dhabi, Eye Institute, Abu Dhabi, United Arab Emirates

    Francesco Pichi

  2. Cleveland Clinic Abu Dhabi, Eye Institute, Abu Dhabi, United Arab Emirates

    Piergiorgio Neri

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Neri, P. (2020). Treatment of Inflammatory Choroidal Neovascular Membranes. In: Pichi, F., Neri, P. (eds) Complications in Uveitis. Springer, Cham. https://doi.org/10.1007/978-3-030-28392-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-28392-6_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-28391-9

  • Online ISBN: 978-3-030-28392-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation